Shanta Gold's CEO explains the Q2 production shortfall and emphasises the cashflow strength of SGH. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Syncona investee Anaveon doses first patient in ANV419 trial

Thu, 24th Jun 2021 10:20

(Alliance News) - Syncona Ltd on Thursday reported its portfolio company Anaveon has dosed its first patient in a trial of a treatment aimed at enhancing patient immune systems.

Immuno-oncology firm Anaveon is currently studying ANV419, a type of protein which has the potential to therapeutically enhance a patient's immune system to better respond to tumours, with the possibility of future use as a treatment against certain cancers.

Life sciences investor Syncona first invested in Anaveon in early 2019, buying a 47% stake for CHF28 million, or GBP21.4 million. According to Syncona's website, it currently holds a 51% stake in Anaveon.

"We are encouraged by Anaveon's strong progress since our first investment in the company in 2019," said Syncona Chief Executive Martin Murphy.

"The first patient dosing comes off the back of pre-clinical data which has shown that ANV419 has the potential to be a best-in-class asset. Whilst not without risk, the clinical data generated by the company will be a critical driver of value and there is a fast timeline for the company to show differentiation against competing products."

Syncona shares were down 1.2% at 212.50 pence in London Thursday morning.

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

Syncona investee Anaveon doses first patient in ANV419 trial

Syncona investee Anaveon doses first patient in ANV419 trial

24 Jun 21 10:20

Syncona gets boost in full-year from life science portfolio

Syncona gets boost in full-year from life science portfolio

17 Jun 21 08:56

Syncona reports positive asset value return in final results

(Sharecast News) - Healthcare investment company Syncona reported year-end net assets of £1.3bn in its final results on Thursday, up from £1.25bn in the prior year.

17 Jun 21 07:46

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

10 Jun 21 16:09

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.